Opendata, web and dolomites

PolyDrug Discovery

Discovery of anticancer polymeric drugs that mimic the action of TRAIL

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PolyDrug Discovery" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.gormleylab.com
 Total cost 173˙857 €
 EC max contribution 173˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2018-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 173˙857.00

Map

 Project objective

Biopharmaceuticals such as monoclonal antibodies (mAbs) and interferons/cytokines have become mainstream since the approval of recombinant human insulin in 1982. However, many challenges such as production costs, output capacity and demanding storage conditions prevent them from realizing their full potential. Therefore, the objective of this action is to develop a polymeric drug (PolyDrug) that mimics the activity of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) for the treatment of breast cancer. To do this, multivalent polymers that display peptides (binding epitopes) with high affinity for death receptor 5 (DR5) will be prepared in high-throughput using combinatorial polymer chemistry. Then, the modern drug discovery process will be applied to identify/develop PolyDrugs with the greatest anticancer potential. This includes library preparation in Work Package 1 (WP1), high-throughput screening and hit to lead in WP2, and lead optimization through cell studies and macromolecular modeling in WP 3. Beyond this scope of this action, these efforts will be followed by preclinical and clinical development within a start-up PolyDrug discovery company. With this innovative PolyDrug discovery process, I hypothesize that I will be able to develop polymeric replacements for current biopharmaceuticals including TRAIL.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POLYDRUG DISCOVERY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POLYDRUG DISCOVERY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GENESIS (2020)

unveilinG cEll-cell fusioN mEdiated by fuSexins In chordateS

Read More  

LiquidEff (2019)

LiquidEff: Algebraic Foundations for Liquid Effects

Read More  

ParkIFNAR (2020)

Soluble IFNAR2 in Parkinson's disease and its role in the regulation of IFNβ in a neuroinflammatory context.

Read More